Cancer of Cervix
Conditions
Interventions
Experiemental group 1:chemotherapy, B-model ultrasound combined with microbubbles of low mechanical index, and hydrogen peroxide solution
Experiemental group 2:chemotherapy, B-model ultrasound combined with microbubbles of high mechanical index, and hydrogen peroxide solution
Experiemental group 3:chemotherapy, VFlash-model ultrasound combined with microbubbles of low mechanical index, and hydrogen peroxide solution
Experiemental group 4:chemotherapy, VFlash-model ultrasound combined with microbubbles of high mechanical index, and hydrogen peroxide solution
Control group:chemotherapy
Sponsors
Xinqiao Hospital, Third Military Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed cervical cancer patients; 2. Female,aged 18 to 75 years; 3. Have a measurable tumor lesion for oncology assessment (ultrasound, CT or MRI); 4. Expected survival of three months or more, PS score 0-2; 5. WBC=3.5×10*9/L; ANC=1.5×10*9/L; PLT=80×10*9/L; Hb=90/L; 6. Normal liver and kidney function; ALT, AST = 2.5 times upper limit of normal; Urea, Cr = 1.25 times upper limit of normal; ALT, AST = 5 times upper limit of normal for patients with liver metastases; 7. Normal heart and lung function; 8. No history of other malignant tumors; 9. Good compliance, no mental disorder; 10. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Do not meet the inclusion criteria; 2. Pregnancy or breast-feeding; 3. Allergy or hypersensitive to chemotherapy drugs; 4. The cervical lesion bleeding severely so that can not be ceased; 5. With massive ascites; 6. Positive lung, brain, or other organs metastasis; 7. During therapeutic course of other anticancer drugs or radiotherapy; 8. Participating in other clinical trials, or less than 4 weeks since the accomplishment of previous chemotherapy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size;Objective response rate;Normal tissue side effects;Postoperative pathology; | — |
Secondary
| Measure | Time frame |
|---|---|
| laboratory examination; | — |
Countries
China
Contacts
Public ContactLiu Zheng
Xinqiao Hospital, Third Military Medical University
Outcome results
None listed